Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
暂无分享,去创建一个
Scott E. Smith | J. Vose | A. Zelenetz | C. Flowers | A. Evens | F. Hernandez-Ilizaliturri | L. Medeiros | C. Nabhan | K. Blum | Shaoying Li | J. Castillo | D. Peace | J. Chavez | A. Mato | A. Sohani | J. Abramson | O. Press | B. Jovanovic | S. Barta | R. Cassaday | David T Yang | F. Lansigan | R. Karmali | J. Jaso | K. Song | T. Fenske | Jonathon B. Cohen | A. Petrich | L. Lee | H. Sun | C. Howlett | D. Landsburg | M. Jaglal | M. Gandhi | N. Reddy | J. Whyman | Camille Adeimy | J. Cohen | C. Handler | S. Rajguru | Saurabh A. Rajguru | Judy P. Tsai | Neil Dalal | N. Shah | K. Shah | Shruthi Melinamani | Jeremy D. Whyman
[1] Sonali M. Smith,et al. MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches , 2014, Cancer.
[2] Michael L. Wang,et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.
[3] S. Schuster,et al. ‘Double‐Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients , 2014, British journal of haematology.
[4] Jeffrey A Jones,et al. Complete response to induction therapy in patients with Myc‐positive and double‐hit non‐Hodgkin lymphoma is associated with prolonged progression‐free survival , 2014, Cancer.
[5] R. Gascoyne,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.
[6] T. Kroll,et al. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? , 2014, Bone Marrow Transplantation.
[7] Michael L. Wang,et al. Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma , 2013, British journal of haematology.
[8] Scott E. Smith,et al. Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis , 2013 .
[9] S. Schuster,et al. “Double-Hit” Cytogenetic Status Is Not Predicted By Baseline Clinicopathologic Characteristics and Is Highly Associated With Overall Survival In B Cell Lymphoma Patients , 2013 .
[10] D. Vesole,et al. Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL) , 2013 .
[11] Michael L. Wang,et al. Double Hit Lymphoma: M.D. Anderson Experience , 2013 .
[12] R. Gascoyne,et al. Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia , 2013 .
[13] Shaoying Li,et al. Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma? , 2013 .
[14] L. Staudt,et al. Low-intensity therapy in adults with Burkitt's lymphoma. , 2013, The New England journal of medicine.
[15] J. Friedberg,et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. , 2013, The New England journal of medicine.
[16] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[17] D. Neuberg,et al. Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy , 2012 .
[18] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Rosenwald,et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .
[20] K. Young,et al. High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma , 2012, The American journal of surgical pathology.
[21] L. Medeiros,et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.
[22] T. Molina,et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.
[23] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[24] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[26] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[27] S. Barrans,et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). , 2008, Blood.
[28] S. Yoon,et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.
[29] L. Staudt,et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Gascoyne,et al. Clinical Trials and Observations , 2005 .
[31] F. Craig. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis , 2007 .
[32] E. Schuuring,et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Gordon,et al. Advanced diffuse non‐Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study , 1995, Cancer.
[34] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.